Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia (Nasdaq: ELUT) announced on March 4, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price) and Rule 5550(b)(2) (minimum market value of listed securities).

Rhea-AI Summary

Elutia (Nasdaq: ELUT) announced on March 4, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price) and Rule 5550(b)(2) (minimum market value of listed securities).

Nasdaq advised the company is now in full compliance with continued listing requirements and that these matters are closed, and Elutia’s Class A common stock will remain listed and traded on the Nasdaq Capital Market under the symbol ELUT.

Positive

• Regained Nasdaq compliance with Rule 5550(a)(2) minimum bid price
• Regained Nasdaq compliance with Rule 5550(b)(2) minimum market value
• Listing maintained — Class A common stock remains on Nasdaq Capital Market under ELUT
• Nasdaq closed the matters, removing pending listing-related uncertainty for shareholders

Negative

• None.

Argus Mar 4 session

-2.46% close to close Open Argus

Details

News Market Reaction – ELUT

In the Mar 4 session, ELUT declined 2.46%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirmed that ELUT regained compliance with Nasdaq’s minimum bid price and market...

Analysis

This announcement confirmed that ELUT regained compliance with Nasdaq’s minimum bid price and market value requirements, ensuring continued listing on the Nasdaq Capital Market. It follows recent updates on leadership, preliminary financials, and the NXT-41x program. Investors may watch whether the share price, currently below the 200-day MA of 1.31 and far under the 3.46 52-week high, sustains stability after the compliance milestone.

Key Figures

Nasdaq Listing Rule: 5550(a)(2) Nasdaq Listing Rule: 5550(b)(2)

Nasdaq Listing Rule

5550(a)(2)

Minimum bid price requirement referenced for compliance

Nasdaq Listing Rule

5550(b)(2)

Minimum market value of listed securities requirement referenced

Historical Context

5 past events · Latest: Mar 02

5 events

1. Mar 02

   CCO appointment

   24h Move

   -0.9%

   Named Pete Ligotti CCO to lead NXT-41x commercialization in breast surgery market.

2. Feb 25

   Earnings date set

   24h Move

   +5.5%

   Announced Q4 2025 earnings release and conference call schedule on Mar 11, 2026.

3. Feb 18

   Workplace award

   24h Move

   +4.3%

   Earned 2026 Great Place to Work Certification highlighting culture and workforce metrics.

4. Jan 12

   Prelim Q4 results

   24h Move

   -4.8%

   Reported preliminary Q4 2025 results and NXT-41x milestones with strengthened finances.

5. Jan 09

   Conference presentation

   24h Move

   +4.7%

   Planned NXT-41x presentation at Global BioInnovation Forum during JP Morgan week.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

minimum bid price requirement, market value of listed securities, nasdaq capital market

3 terms

minimum bid price requirement regulatory

"regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

market value of listed securities regulatory

"and the minimum market value of listed securities requirement set forth in Nasdaq Listing"

Market value of listed securities is the market value of the shares a company has listed on an exchange, calculated as the closing bid price multiplied by the number of listed shares. Exchanges use it as a continued-listing standard, so a company that stays under the required minimum receives a deficiency notice and is given a set period to recover before facing delisting.

nasdaq capital market regulatory

"stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2). As a result, the Company is now in full compliance with all Nasdaq continued listing requirements, and Nasdaq has advised that these matters are now closed. The Company’s Class A common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “ELUT.”

“We are pleased to have regained compliance with Nasdaq continued listing requirements,” said Matt Ferguson, Chief Financial Officer of Elutia. “We see this recent increase in our share price and market value as a direct reflection of investors’ confidence in our demonstrated drug-eluting biomatrix technology platform, the large market opportunity we’re addressing and the outstanding capabilities of the Elutia CRU.”

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the securities laws. Forward-looking statements in this report include any statements about Elutia’s ability to maintain compliance in the future with applicable Nasdaq continued listing standards, maintain the listing of its Class A common stock on the Nasdaq Capital Market, and investors’ confidence in Elutia’s future opportunities. Forward-looking statements are based on management’s current assumptions and expectations of future events; actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties, including those found in Elutia’s periodic reports. Consequently, you should not rely on forward-looking statements as predictions of future events. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements.

Investors:
Elutia Investor Relations
ir@elutia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Elutia (ELUT) announce on March 4, 2026 about Nasdaq compliance?

Elutia said it has regained compliance with Nasdaq minimum bid price and market value rules. According to the company, Nasdaq advised the matters are closed and Elutia’s Class A common stock will continue trading on the Nasdaq Capital Market under symbol ELUT.

Does the March 4, 2026 notice mean Elutia (ELUT) will remain listed on Nasdaq?

Yes — Elutia confirmed its Class A common stock will remain listed and traded on Nasdaq. According to the company, Nasdaq closed the compliance matters after the company met Rules 5550(a)(2) and 5550(b)(2).

Which Nasdaq listing rules did Elutia (ELUT) regain compliance with on March 4, 2026?

Elutia regained compliance with Nasdaq Listing Rule 5550(a)(2) and 5550(b)(2). According to the company, those rules cover the minimum bid price and the minimum market value of listed securities respectively.

What is the investor significance of Elutia (ELUT) regaining Nasdaq compliance?

The announcement removes imminent listing-viability uncertainty for shareholders. According to the company, Nasdaq closed the matters, allowing continued trading of Class A common stock under ELUT, which may support investor confidence.

When did Elutia (ELUT) confirm Nasdaq closed its compliance matters?

Elutia confirmed on March 4, 2026 that Nasdaq advised the compliance matters are closed. According to the company, this notice follows the company meeting the minimum bid price and market value requirements.

How did Elutia (ELUT) describe the reason for the share price improvement tied to Nasdaq compliance?

Elutia linked the share price increase to investor confidence in its technology and market opportunity. According to the company, the rise reflects confidence in its drug-eluting biomatrix platform and the capabilities of the Elutia CRU.